
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics is well-positioned for growth due to its diverse pipeline of novel therapies targeting unmet medical needs in cancer, skin toxicities, Alzheimer's, and weight management. The company has shown promising results in early clinical trials, with no serious adverse events and sustained response in its topical formulation for EGFR therapy-associated skin toxicities. With continued development and potential partnerships, Hoth has the potential to become a leader in the biopharmaceutical industry.
Bears say
Hoth Therapeutics is deploying AI infrastructure to support the development of HT-KIT, an orphan-designated therapy targeting rare KIT-driven cancers. The program has received Orphan Drug Designation and has completed GLP-validated bioanalytical methods to support IND submission. With potential approvals in multiple EU countries and encouraging data in EGFR inhibitor-associated rash and a VA-led GDNF study, as well as progress on joint venture programs, Hoth could see incremental value in its dual-track strategy.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares